<DOC>
	<DOCNO>NCT00258635</DOCNO>
	<brief_summary>The purpose study assess immunological difference three RagweedMATAMPL treatment arm compare placebo respect immunoglobulin level . In addition , study ass reduce allergenicity modify Ragweed Pollen contain RagweedMATAMPL compare unmodified native allergen use skin prick testing .</brief_summary>
	<brief_title>Investigation Safety+Efficacy Different Doses RagweedMATAMPL ; Assessment Residual Allergenicity Using Skin Prick Test</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<criteria>1 . Patients must male female age 1850 year , inclusive . 2 . Patients must positive skin prick test ragweed allergen ( wheal ≥5 mm large negative control ) . 3 . Positive skin prick test positive histamine control wheal ( long ) diameter ≥3 mm . 4 . Negative skin prick test negative control ( redness , wheal acceptable ) . 5 . Specific IgE ragweed document radioallergosorbent equivalent test class ≥2 . 6 . History least 1 season moderate severe seasonal rhinoconjunctivitis due IgE mediate allergy pollen ragweed derive allergic history . 7 . Patients must score disease severity questionnaire moderate severe . 8 . Males nonpregnant , nonlactating female postmenopausal naturally surgically sterile ( hysterectomy ; bilateral oophorectomy ; bilateral tubal ligation surgery least 6 week prior study initiation ) . Females childbearing potential confirm absence pregnancy accord negative urine pregnancy test must use one follow acceptable birth control method : 1 . Intrauterine device place least 90 day ; 2 . Barrier method ( condom diaphragm ) spermicide ; 3 . Stable hormonal contraceptive least 90 day prior study study completion ; 4 . Abstinence ; 5 . Nonheterosexual lifestyle ; 6 . Vasectomized partner least 90 day . 9 . Patients normally active otherwise judge good health basis medical history , physical examination , routine laboratory test . 10 . Patients must willing able attend require study visit . 11 . Patients must able follow instruction . 12 . Patients must willing able give write informed consent study . Consent must obtain prior initiation washout period . 13 . Spirometry Screening demonstrates FEV1 ≥ 80 % predict FEV1/FVC ≥70 % , applicable 1 . Acute subacute atopic dermatitis and/or urticaria factitia and/or urticaria due physical chemical influence and/or chronic dermatitis . 2 . Patient moderate severe asthma . 3 . Visual inspection forearm indicate potential problem conduct interpretation skin prick test ; forearm must available test . 4 . History presence diabetes ( insulin dependent nondependent ) , cancer clinically significant cardiac , metabolic renal , hematologic diseases disorder . 5 . Recent clinically significant history ( within 2 year ) hepatic gastrointestinal , dermatologic , venereal , neurologic psychiatric disease disorder . 6 . Any clinically significant ( determined Investigator ) abnormal laboratory value Visit 1 . 7 . Clinically relevant sensitivity perennial allergen [ house dust mite ( Dermatophagoides pteronyssinus , Dermatophagoides farinae ) , mold ( Cladosporium cladosporioides , Alternaria alternata , Penicillium chrysogenum , Aspergillus fumigatus ) , cat epithelium ( Felis domesticus ) , dog epithelium ( Canis familiaris ) horse epithelium ( Equus caballus ) ] , document positive case history , prick test wheal size ≥3 mm diameter large negative control radioallergosorbent test class ≥2 . Exceptions : The Investigator may judge sensitivity clinically relevant . 8 . Clinically relevant sensitivity seasonal allergen [ mountain cedar , ash , birch , elm , maple , hickory , oak , cottonwood , bermuda grass grass mix ] document positive case history , prick test wheal size ≥3 mm diameter large negative control radioallergosorbent test class ≥2 . Exceptions : list allergen must test common Investigator´s region , common region , overlap exists allergen ( ) season treatment post treatment phase study . Furthermore , subject exclude Investigator may judge sensitivity clinically relevant . 9 . Secondary alteration affect organ ( i.e . emphysema , bronchiectasis ) . 10 . History autoimmune disease ( e.g . liver , kidney , thyroid , nervous system ) , and/or rheumatoid disease . 11 . Patient take ßblockers indication include eye drop . 12 . Patient allow receive adrenalin . 13 . Patients tyrosine metabolism disturb , especially case tyrosinemia alkaptonuria . 14 . Presence disease pathogenesis interfere immune response patient receive medication could influence result study . 15 . Documented evidence acute significant chronic infection . 16 . History anaphylaxis , include anaphylactic food allergy , insect venom anaphylaxis , exercise drug induce anaphylaxis . 17 . Documented history angioedema . 18 . Hypersensitivity excipients study medication . 19 . Previous current immunotherapy comparable ragweed allergen extract . 20 . Currently use antiallergy medication drug antihistaminic activity . 21 . Patients currently participate clinical trial expose study medication within last 30 day . 22 . Patients communicate reliably Investigator likely cooperate requirement study . 23 . Patient pregnant planning pregnancy and/or lactate . 24 . Patient receive treatment preparation contain MPL® past 12 month . 25 . Concurrent use prohibit medication ( ) , inadequate washout medication . 26 . Any systemic disorder could interfere evaluation study medication ( ) . 27 . Clinical history ( within 2 year ) drug alcohol abuse would , opinion Investigator , interfere patient 's participation study . 28 . Patient positive urine drug screen ( cocaine metabolite , cannabinoids , opiate , PCP , amphetamine ) , positive alcohol saliva test . 29 . Study site staff immediate relative study site staff individual would access clinical study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Specific Immunotherapy</keyword>
</DOC>